Johnson & Johnson‘s (NYSE: JNJ) pharmaceuticals business in on pace to account for half of the company’s sales, and it’s a major source of the company’s earnings. However, the company faces stiffening competition, and that’s forcing J&J to respond with price cuts. Can J&J overcome those headwinds?